Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: Focus on docetaxel

Seminars in Oncology

Volumn 28, Issue 3 SUPPL. 9, 2001, Pages 26-32

  Gandara, David R ^a   Lara Jr, Primo N ^a   Goldberg, Zelanna ^a   Lau, Derick H M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RADIOSENSITIZING AGENT; VINBLASTINE; VINDESINE;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; RADIATION PNEUMONIA; THROMBOCYTOPENIA;

EID: 0034974040     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24605     Document Type: Article

References (31)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
3. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group study
4. Preliminary results of a phase III trial in regionally advanced non-small cell lung cancer
5. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer
6. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomised trial in 535 patients
7. Clinical studies in non-small cell lung cancer: The CALGB experience
8. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431)
9. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
10. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
11. Phase III comparison of sequential vs concurrent chemo-radiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410
12. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
13. A prospective randomized trial of docetaxel (taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
14. Randomized phase III study of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
15. Docetaxel enhances tumor radioresponse in vivo
16. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
17. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial of 353 patients
18. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer
19. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A Californian Cancer Consortium phase II trial
20. CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC)
21. Phase I study of docetaxel with concomitant thoracic radiation therapy
22. Clinical studies of docetaxel (taxotere) and concomitant chest therapy
23. A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (LA-NSCLC)
24. Concomitant docetaxel, cisplatin and radiation (XRT) in the treatment of locally advanced non-small cell lung cancer (NSCLC): A phase I study
25. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial
26. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
27. Pathological stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consolidation of docetaxel following concurrent chemoradiotherapy (SWOG 9504)
28. Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer. A Southwest Oncology Group phase II study (S9019)
29. Induction therapy before surgery for non-small cell lung cancer
30. p27 induction as a potential p53-independent mechanism of apoptotic response to taxanes in non-small cell lung carcinoma (NSCLC)
31. Discussant session